Experienced in Singleton-Merten Syndrome

Benedicte Heron-Longe

Paris, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Singleton-Merten Syndrome
Paris, FR 
OverviewLocationsClinical Research

Overview

Benedicte Heron-Longe practices in Paris, France. Ms. Heron-Longe is rated as an Experienced expert by MediFind in the treatment of Singleton-Merten Syndrome. Her top areas of expertise are Mucopolysaccharidosis Type 3 (MPS III, Sanfilippo Syndrome), Niemann-Pick Disease, Mucopolysaccharidoses (MPS), and Non-Langerhans-Cell Histiocytosis.

Her clinical research consists of co-authoring 69 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Singleton-Merten Syndrome.

Gender
Female

Locations

Paris, France
Other Locations
La Roche, France
France
Avenue Du 14-Juillet, Bondy, 93143, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH for Mucopolysaccharidosis (MPS) IIIA
Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH for Mucopolysaccharidosis (MPS) IIIA
Enrollment Status: Recruiting
Publish Date: July 17, 2025
Intervention Type: Drug, Biological
Study Drug: ABO-102
Study Phase: Phase 2/Phase 3
Arimoclomol Prospective Double-blind, Randomised, Placebo-controlled Study in Patients Diagnosed With Niemann-Pick Disease Type C
Arimoclomol Prospective Double-blind, Randomised, Placebo-controlled Study in Patients Diagnosed With Niemann-Pick Disease Type C
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drug: Arimoclomol
Study Phase: Phase 2/Phase 3
An Open-Label Adaptive-Design Study of Intracisternal Adenoassociated Viral Vector Serotype rh.10 Carrying the Human β-Galactosidase cDNA for Treatment of GM1 Gangliosidosis
An Open-Label Adaptive-Design Study of Intracisternal Adenoassociated Viral Vector Serotype rh.10 Carrying the Human β-Galactosidase cDNA for Treatment of GM1 Gangliosidosis
Enrollment Status: Terminated
Publish Date: June 09, 2023
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2
A Long-term Follow-up Study of Patients With MPS IIIB From Gene Therapy Clinical Trials Involving the Administration of ABO-101 (rAAV9.CMV.hNAGLU)
A Long-term Follow-up Study of Patients With MPS IIIB From Gene Therapy Clinical Trials Involving the Administration of ABO-101 (rAAV9.CMV.hNAGLU)
Enrollment Status: Terminated
Publish Date: May 31, 2022
Intervention Type: Biological
Phase I/II Gene Transfer Clinical Trial of rAAV9.CMV.hNAGLU for Mucopolysaccharidosis (MPS) IIIB
Phase I/II Gene Transfer Clinical Trial of rAAV9.CMV.hNAGLU for Mucopolysaccharidosis (MPS) IIIB
Enrollment Status: Terminated
Publish Date: May 05, 2022
Intervention Type: Biological
Study Drug: rAAV9.CMV.hNAGLU
Study Phase: Phase 1/Phase 2
Open-label, Single-arm, Multi-center Study of Intracerebral Administration of Adeno-associated Viral (AAV) Serotype rh.10 Carrying Human N-sulfoglucosamine Sulfohydrolase (SGSH) cDNA for Treatment of Mucopolysaccharidosis Type IIIA
Open-label, Single-arm, Multi-center Study of Intracerebral Administration of Adeno-associated Viral (AAV) Serotype rh.10 Carrying Human N-sulfoglucosamine Sulfohydrolase (SGSH) cDNA for Treatment of Mucopolysaccharidosis Type IIIA
Enrollment Status: Unknown
Publish Date: August 31, 2021
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C in Order to Characterise the Individual Patient Disease Profile and Historic Signo-symptomatology Progression Pattern
A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C in Order to Characterise the Individual Patient Disease Profile and Historic Signo-symptomatology Progression Pattern
Enrollment Status: Completed
Publish Date: May 18, 2017
View 6 Less Clinical Trials

69 Total Publications

Systematic analysis of snRNA genes reveals frequent RNU2-2 variants in dominant and recessive developmental and epileptic encephalopathies.
Systematic analysis of snRNA genes reveals frequent RNU2-2 variants in dominant and recessive developmental and epileptic encephalopathies.
Journal: medRxiv : the preprint server for health sciences
Published: September 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Heron-Longe's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 40 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile